Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Targeted Therapy in Oropharyngeal Squamous Cell Carcinoma: The Implications of HPV for Therapy

Targeted Therapy in Oropharyngeal Squamous Cell Carcinoma: The Implications of HPV for Therapy Oropharyngeal cancers caused by human papillomaviruses (HPV) have a different epidemiology, prognosis, genetic mutational landscape, response to treatment, and outcome when compared to HPV-negative cancers. In this review, a summary of our current understanding of HPV in head and neck cancer and the important advances that have shown HPV to be an etiological agent are discussed. HPV-positive and HPV-negative tumors are compared discussing clinicopathological factors, prognosis, outcome following treatment, and the molecular and genetic differences. Currently, the standard of care for oropharyngeal cancer is both surgery and post-operative radiotherapy with or without cisplatin or concurrent chemo-radiotherapy. The latter is used more often, especially in cancers of tonsil and base of tongue. However, there is increased interest in trying to de-intensify treatment and in the development of new treatments to target the underlying different molecular pathways of HPV-positive cancers. The current clinical trials involving surgery, chemotherapy, and radiation therapy are discussed. The new targeted treatments are also summarized. Although there is currently is no evidence from prospective studies to support a change in the treatment algorithm, the treatment options for patients with HPV-positive disease are likely to change in the future. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Oncology and Therapy Springer Journals

Targeted Therapy in Oropharyngeal Squamous Cell Carcinoma: The Implications of HPV for Therapy

Hay, Ashley; Ganly, Ian
Oncology and Therapy , Volume 3 (2) – Sep 9, 2015
Download PDF
29 pages

Loading next page...
 
/lp/springer-journals/targeted-therapy-in-oropharyngeal-squamous-cell-carcinoma-the-5y760hgvcU
Publisher
Springer Journals
Copyright
Copyright © 2015 by Springer Healthcare
Subject
Medicine & Public Health; Internal Medicine
ISSN
2366-1070
eISSN
2195-6022
DOI
10.1007/s40487-015-0008-5
Publisher site
See Article on Publisher Site

Abstract

Oropharyngeal cancers caused by human papillomaviruses (HPV) have a different epidemiology, prognosis, genetic mutational landscape, response to treatment, and outcome when compared to HPV-negative cancers. In this review, a summary of our current understanding of HPV in head and neck cancer and the important advances that have shown HPV to be an etiological agent are discussed. HPV-positive and HPV-negative tumors are compared discussing clinicopathological factors, prognosis, outcome following treatment, and the molecular and genetic differences. Currently, the standard of care for oropharyngeal cancer is both surgery and post-operative radiotherapy with or without cisplatin or concurrent chemo-radiotherapy. The latter is used more often, especially in cancers of tonsil and base of tongue. However, there is increased interest in trying to de-intensify treatment and in the development of new treatments to target the underlying different molecular pathways of HPV-positive cancers. The current clinical trials involving surgery, chemotherapy, and radiation therapy are discussed. The new targeted treatments are also summarized. Although there is currently is no evidence from prospective studies to support a change in the treatment algorithm, the treatment options for patients with HPV-positive disease are likely to change in the future.

Journal

Oncology and Therapy – Springer Journals

Published: Sep 9, 2015

References

  • National Cancer Database report on cancer of the head and neck: 10-year update
    Cooper, JS; Porter, K; Mallin, K; Hoffman, HT; Weber, RS; Ang, KK
  • The rise of HPV-positive oropharyngeal cancers in the United States
    Fakhry, C; Cohen, E
  • Incidence trends for human papillomavirus-related and -unrelated oral squamous cell carcinomas in the United States
    Chaturvedi, AK; Engels, EA; Anderson, WF; Gillison, ML
  • Worldwide trends in incidence rates for oral cavity and oropharyngeal cancers
    Chaturvedi, AK; Anderson, WF; Lortet-Tieulent, J; Curado, MP; Ferlay, J; Franceschi, S
  • Trends in head and neck cancer incidence in relation to smoking prevalence: an emerging epidemic of human papillomavirus-associated cancers?
    Sturgis, EM; Cinciripini, PM
  • Trends in incidence and prognosis for head and neck cancer in the United States: a site-specific analysis of the SEER database
    Carvalho, AL; Nishimoto, IN; Califano, JA; Kowalski, LP
  • Morphological and immunohistochemical evidence suggesting human papillomavirus (HPV) involvement in oral squamous cell carcinogenesis
    Syrjanen, K; Syrjanen, S; Lamberg, M; Pyrhonen, S; Nuutinen, J
  • Evidence for a causal association between human papillomavirus and a subset of head and neck cancers
    Gillison, ML; Koch, WM; Capone, RB; Spafford, M; Westra, WH; Wu, L
  • Human papillomavirus as a marker of the natural history and response to therapy of head and neck squamous cell carcinoma
    Ang, KK; Sturgis, EM
  • Biology of human papillomavirus infections in head and neck carcinogenesis
    Rautava, J; Syrjanen, S
  • Human papillomavirus is more common in base of tongue than in mobile tongue cancer and is a favorable prognostic factor in base of tongue cancer patients
    Dahlgren, L; Dahlstrand, HM; Lindquist, D; Hogmo, A; Bjornestal, L; Lindholm, J
  • Human papillomavirus genotype distribution in oropharynx and oral cavity cancer in France-The EDiTH VI study
    St Guily, JL; Jacquard, AC; Pretet, JL; Haesebaert, J; Beby-Defaux, A; Clavel, C
  • Molecular mechanisms of HPV induced carcinogenesis in head and neck
    Rampias, T; Sasaki, C; Psyrri, A
  • Immunohistochemical markers of tonsillar crypt epithelium
    Surjan, L
  • HPV integration begins in the tonsillar crypt and leads to the alteration of p16, EGFR and c-myc during tumor formation
    Kim, SH; Koo, BS; Kang, S; Park, K; Kim, H; Lee, KR
  • A novel integrin (alpha E beta 4) from human epithelial cells suggests a fourth family of integrin adhesion receptors
    Kajiji, S; Tamura, RN; Quaranta, V
  • Different heparan sulfate proteoglycans serve as cellular receptors for human papillomaviruses
    Shafti-Keramat, S; Handisurya, A; Kriehuber, E; Meneguzzi, G; Slupetzky, K; Kirnbauer, R
  • Epidemiology of oral human papillomavirus infection
    Chung, CH; Bagheri, A; D’Souza, G
  • Prevalence of oral HPV infection in the United States, 2009–2010
    Gillison, ML; Broutian, T; Pickard, RK; Tong, ZY; Xiao, W; Kahle, L
  • Oral human papillomavirus in healthy individuals: a systematic review of the literature
    Kreimer, AR; Bhatia, RK; Messeguer, AL; Gonzalez, P; Herrero, R; Giuliano, AR
  • Case-control study of human papillomavirus and oropharyngeal cancer
    D’Souza, G; Kreimer, AR; Viscidi, R; Pawlita, M; Fakhry, C; Koch, WM
  • Human papillomavirus and oropharynx cancer: biology, detection and clinical implications
    Allen, CT; Lewis, JS; El-Mofty, SK; Haughey, BH; Nussenbaum, B
  • Reconstitution of p53-ubiquitinylation reactions from purified components: the role of human ubiquitin-conjugating enzyme UBC4 and E6-associated protein (E6AP)
    Rolfe, M; Beer-Romero, P; Glass, S; Eckstein, J; Berdo, I; Theodoras, A
  • HPV-related oropharyngeal cancers: from pathogenesis to new therapeutic approaches
    Tornesello, ML; Perri, F; Buonaguro, L; Ionna, F; Buonaguro, FM; Caponigro, F
  • Human papillomavirus association with head and neck cancers: understanding virus biology and using it in the development of cancer diagnostics
    Strati, K; Lambert, PF
  • The human papillomavirus E6 PDZ binding motif: from Life Cycle to Malignancy
    Ganti, K; Broniarczyk, J; Manoubi, W; Massimi, P; Mittal, S; Pim, D
  • Meta-analysis of the impact of human papillomavirus (HPV) on cancer risk and overall survival in head and neck squamous cell carcinomas (HNSCC)
    Dayyani, F; Etzel, CJ; Liu, M; Ho, CH; Lippman, SM; Tsao, AS
  • Variable expression of the forgotten oncogene E5 in HPV-positive oropharyngeal cancer
    Um, SH; Mundi, N; Yoo, J; Palma, DA; Fung, K; MacNeil, D
  • HPV-related squamous cell carcinoma of the head and neck: an update on testing in routine pathology practice
    Bishop, JA; Lewis, JS; Rocco, JW; Faquin, WC
  • Molecular characterization of p16-immunopositive but HPV DNA-negative oropharyngeal carcinomas
    Rietbergen, MM; Snijders, PJ; Beekzada, D; Braakhuis, BJ; Brink, A; Heideman, DA
  • Human papillomavirus and head and neck cancer: a systematic review and meta-analysis
    Hobbs, CG; Sterne, JA; Bailey, M; Heyderman, RS; Birchall, MA; Thomas, SJ
  • Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review
    Kreimer, AR; Clifford, GM; Boyle, P; Franceschi, S
  • The molecular biology of head and neck cancer
    Leemans, CR; Braakhuis, BJ; Brakenhoff, RH
  • Human papillomavirus-associated head and neck cancer is a distinct epidemiologic, clinical, and molecular entity
    Gillison, ML
  • Squamous cell carcinoma of the head and neck outside the oropharynx is rarely human papillomavirus related
    Upile, NS; Shaw, RJ; Jones, TM; Goodyear, P; Liloglou, T; Risk, JM
  • Age, sexual behavior and human papillomavirus infection in oral cavity and oropharyngeal cancers
    Smith, EM; Ritchie, JM; Summersgill, KF; Klussmann, JP; Lee, JH; Wang, D
  • Human papillomavirus (HPV) DNA in tonsillar cancer: clinical correlates, risk of relapse, and survival
    Mellin, H; Friesland, S; Lewensohn, R; Dalianis, T; Munck-Wikland, E
  • Jatin Shah’s head and neck surgery and oncology
    Shah, JP; Patel, SG; Singh, B
  • The INHANCE consortium: toward a better understanding of the causes and mechanisms of head and neck cancer
    Winn, DM; Lee, YC; Hashibe, M; Boffetta, P
  • Human papillomavirus positive squamous cell carcinoma of the oropharynx: a radiosensitive subgroup of head and neck carcinoma
    Lindel, K; Beer, KT; Laissue, J; Greiner, RH; Aebersold, DM
  • Human papillomavirus, smoking status and outcomes in tonsillar squamous cell carcinoma
    Hong, AM; Martin, A; Chatfield, M; Jones, D; Zhang, M; Armstrong, B
  • Distinct risk factor profiles for human papillomavirus type 16-positive and human papillomavirus type 16-negative head and neck cancers
    Gillison, ML; D’Souza, G; Westra, W; Sugar, E; Xiao, W; Begum, S
  • Tobacco use and oral HPV-16 infection
    Fakhry, C; Gillison, ML; D’Souza, G
  • Human papillomavirus and rising oropharyngeal cancer incidence in the United States
    Chaturvedi, AK; Engels, EA; Pfeiffer, RM; Hernandez, BY; Xiao, W; Kim, E
  • Cystic lymph node metastasis in patients with head and neck cancer: an HPV-associated phenomenon
    Goldenberg, D; Begum, S; Westra, WH; Khan, Z; Sciubba, J; Pai, SI
  • Epidemiology of HPV-associated oropharyngeal cancer
    Pytynia, KB; Dahlstrom, KR; Sturgis, EM
  • Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial
    Fakhry, C; Westra, WH; Li, S; Cmelak, A; Ridge, JA; Pinto, H
  • Survival of squamous cell carcinoma of the head and neck in relation to human papillomavirus infection: review and meta-analysis
    Ragin, CC; Taioli, E
  • Human papillomavirus and survival of patients with oropharyngeal cancer
    Ang, KK; Harris, J; Wheeler, R; Weber, R; Rosenthal, DI; Nguyen-Tan, PF
  • Impact of tumor HPV status on outcome in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck receiving chemotherapy with or without cetuximab: retrospective analysis of the phase III EXTREME trial
    Vermorken, JB; Psyrri, A; Mesia, R; Peyrade, F; Beier, F; Blas, B
  • Human papillomavirus-associated oropharynx cancer (HPV-OPC): treatment options
    Chau, NG; Rabinowits, G; Haddad, RI
  • AJCC cancer staging atlas: a companion to the seventh editions of the AJCC cancer staging manual and handbook
    Compton, CC; Greene, FL
  • Changing prognostic significance of tumor stage and nodal stage in patients with squamous cell carcinoma of the oropharynx in the human papillomavirus era
    Keane, FK; Chen, YH; Neville, BA; Tishler, RB; Schoenfeld, JD; Catalano, PJ
  • Detailed analysis of clinicopathologic factors demonstrate distinct difference in outcome and prognostic factors between surgically treated hpv-positive and negative oropharyngeal cancer
    Iyer, NG; Dogan, S; Palmer, F; Rahmati, R; Nixon, IJ; Lee, N
  • Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1
    Agrawal, N; Frederick, MJ; Pickering, CR; Bettegowda, C; Chang, K; Li, RJ
  • The mutational landscape of head and neck squamous cell carcinoma
    Stransky, N; Egloff, AM; Tward, AD; Kostic, AD; Cibulskis, K; Sivachenko, A
  • Comprehensive genomic characterization of head and neck squamous cell carcinomas
  • TP53 mutations and survival in squamous-cell carcinoma of the head and neck
    Poeta, ML; Manola, J; Goldwasser, MA; Forastiere, A; Benoit, N; Califano, JA
  • EGFR-directed treatments in SCCHN
    Vokes, EE; Seiwert, TY
  • Impact of human papilloma virus infection on the response of head and neck cancers to anti-epidermal growth factor receptor antibody therapy
    Pogorzelski, M; Ting, S; Gauler, TC; Breitenbuecher, F; Vossebein, I; Hoffarth, S
  • Differential expression and activation of NF-kappaB family proteins during oral carcinogenesis: role of high risk human papillomavirus infection
    Mishra, A; Bharti, AC; Varghese, P; Saluja, D; Das, BC
  • Distinct mechanisms of TGF-beta1-mediated epithelial-to-mesenchymal transition and metastasis during skin carcinogenesis
    Han, G; Lu, SL; Li, AG; He, W; Corless, CL; Kulesz-Martin, M
  • Survival and human papillomavirus in oropharynx cancer in TAX 324: a subset analysis from an international phase III trial
    Posner, MR; Lorch, JH; Goloubeva, O; Tan, M; Schumaker, LM; Sarlis, NJ
  • Stage III and IV cancers of the oropharynx: results of a randomized study of Gortec comparing radiotherapy alone with concomitant chemotherapy
    Calais, G; Alfonsi, M; Bardet, E; Sire, C; Germain, T; Bergerot, P
  • HPV-associated head and neck cancer: a virus-related cancer epidemic
    Marur, S; D’Souza, G; Westra, WH; Forastiere, AA
  • Prospects for prevention of HPV-driven oropharynx cancer
    Kreimer, AR
  • Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic
    Kirnbauer, R; Booy, F; Cheng, N; Lowy, DR; Schiller, JT
  • A review of clinical trials of human papillomavirus prophylactic vaccines
    Schiller, JT; Castellsague, X; Garland, SM
  • Reduced prevalence of oral human papillomavirus (HPV) 4 years after bivalent HPV vaccination in a randomized clinical trial in Costa Rica
    Herrero, R; Quint, W; Hildesheim, A; Gonzalez, P; Struijk, L; Katki, HA
  • A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women
    Joura, EA; Giuliano, AR; Iversen, OE; Bouchard, C; Mao, C; Mehlsen, J
  • Associations between oral HPV16 infection and cytopathology: evaluation of an oropharyngeal “pap-test equivalent” in high-risk populations
    Fakhry, C; Rosenthal, BT; Clark, DP; Gillison, ML
  • European Prospective Investigation into Cancer and Nutrition (EPIC): study populations and data collection
    Riboli, E; Hunt, KJ; Slimani, N; Ferrari, P; Norat, T; Fahey, M
  • Evaluation of human papillomavirus antibodies and risk of subsequent head and neck cancer
    Kreimer, AR; Johansson, M; Waterboer, T; Kaaks, R; Chang-Claude, J; Drogen, D
  • The role of surgery for HPV-associated head and neck cancer
    Mydlarz, WK; Chan, JY; Richmon, JD
  • Oropharyngeal carcinoma treated with radiotherapy: a 30-year experience
    Fein, DA; Lee, WR; Amos, WR; Hinerman, RW; Parsons, JT; Mendenhall, WM
  • Factors associated with severe late toxicity after concurrent chemoradiation for locally advanced head and neck cancer: an RTOG analysis
    Machtay, M; Moughan, J; Trotti, A; Garden, AS; Weber, RS; Cooper, JS
  • Transoral laser microsurgery as primary treatment for advanced-stage oropharyngeal cancer: a United States multicenter study
    Haughey, BH; Hinni, ML; Salassa, JR; Hayden, RE; Grant, DG; Rich, JT
  • Decision management in transoral robotic surgery (tors): Indications, individual patient selection, and role in the multidisciplinary treatment of head and neck cancer from a european perspective
    Lorincz, BB; Jowett, N; Knecht, R
  • Experience in endoscopic laser surgery of malignant tumours of the upper aero-digestive tract
    Steiner, W
  • The role of transoral robotic surgery in the management of oropharyngeal cancer: a review of the literature
    Dowthwaite, SA; Franklin, JH; Palma, DA; Fung, K; Yoo, J; Nichols, AC
  • A systematic review of transoral robotic surgery and radiotherapy for early oropharynx cancer: a systematic review
    Almeida, JR; Byrd, JK; Wu, R; Stucken, CL; Duvvuri, U; Goldstein, DP
  • Oncologic, functional and surgical outcomes of primary Transoral Robotic Surgery for early squamous cell cancer of the oropharynx: a systematic review
    Kelly, K; Johnson-Obaseki, S; Lumingu, J; Corsten, M
  • Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck
    Bonner, JA; Harari, PM; Giralt, J; Azarnia, N; Shin, DM; Cohen, RB
  • De-escalation treatment protocols for human papillomavirus-associated oropharyngeal squamous cell carcinoma: a systematic review and meta-analysis of current clinical trials
    Masterson, L; Moualed, D; Liu, ZW; Howard, JE; Dwivedi, RC; Tysome, JR
  • Lacau St Guily J. Oropharyngeal cancers: relationship between epidermal growth factor receptor alterations and human papillomavirus status
    Mirghani, H; Amen, F; Moreau, F; Guigay, J; Hartl, DM
  • Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial
    Vermorken, JB; Stohlmacher-Williams, J; Davidenko, I; Licitra, L; Winquist, E; Villanueva, C
  • New treatment strategies for HPV-positive head and neck cancer
    Kofler, B; Laban, S; Busch, CJ; Lorincz, B; Knecht, R
  • Clinical application of genetically modified T cells in cancer therapy
    Kershaw, MH; Westwood, JA; Slaney, CY; Darcy, PK
  • Administration of HPV DNA vaccine via electroporation elicits the strongest CD8+ T cell immune responses compared to intramuscular injection and intradermal gene gun delivery
    Best, SR; Peng, S; Juang, CM; Hung, CF; Hannaman, D; Saunders, JR
  • Efficacy of DNA vaccines forming e7 recombinant retroviral virus-like particles for the treatment of human papillomavirus-induced cancers
    Lescaille, G; Pitoiset, F; Macedo, R; Baillou, C; Huret, C; Klatzmann, D
  • A phase I dose escalation trial of MAGE-A3- and HPV16-specific peptide immunomodulatory vaccines in patients with recurrent/metastatic (RM) squamous cell carcinoma of the head and neck (SCCHN)
    Zandberg, DP; Rollins, S; Goloubeva, O; Morales, RE; Tan, M; Taylor, R